Showing results (251-260 of 336) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2Masato Terashima, Yosuke Togashi, Katsuaki Sato, et al.JTO Clinical and Research Reports|September 8, 2023
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug TestingTakamasa Koga, Junichi Soh, Akira Hamada, et al.Journal of Molecular Medicine (Berlin, Germany)|February 26, 2003
Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancerYoshiji Yamada, Nobuyuki Hamajima, Tomoyuki Kato, et al.Clinical Lung Cancer|May 9, 2020
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerYoshimasa Shiraishi, Junji Kishimoto, Kentaro Tanaka, et al.Surgical Case Reports|June 28, 2019
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosisShuta Ohara, Kenji Tomizawa, Shigeki Shimizu, et al.Cancer Research|November 18, 2008
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsSeiji Yano, Wei Wang, Qi Li, et al.Clinical Lung Cancer|April 17, 2012
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancersKazuhiko Shien, Tsuyoshi Ueno, Kazunori Tsukuda, et al.Cancer Science|February 15, 2008
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinomaShinichi Toyooka, Toshimi Takano, Takayuki Kosaka, et al.Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyTakamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, et al.The New England Journal of Medicine|October 29, 2010
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsYoung Lim Choi, Manabu Soda, Yoshihiro Yamashita, et al.Pageof 34